What AllMeD Solutions does

AllMeD Solutions Ltd. (TASE: ALMD) is an Israeli publicly-traded medical device company founded in 2001 and headquartered in Or-Aqiva. The company develops, manufactures, and markets minimally invasive medical products internationally, sold directly to hospitals and healthcare institutions for use by physicians treating cardiovascular and urological conditions. Following the 2026 divestitures of Allium Stents (urological stents, sold to Dahlhausen, Germany) and Gardia Medical (embolic protection, sold to Abbott via Cardiovascular Systems, Inc.), the operating business is concentrated on the True Leaf subsidiary's mitral valve regurgitation program — a novel valve-in-docking-station architecture developed toward a first-in-human needle-stick heart valve replacement procedure — together with the retained ProCatid (formerly WIRION) distal embolic protection system, an independent filter unit deliverable on any commercially marketed guide wire. The company is funded through small public-market private placements (TASE), an Israel Innovation Authority R&D grant, and continues to advance TruLeaf through Phase I and II human clinical trials with Ethics Committee approvals in Israel and South Africa. It generates revenue predominantly through hardware sales of medical devices, though no current revenue figure is publicly disclosed in the input data.

Name

AllMeD Solutions

Legal name

AllMeD Solutions Ltd.

Website

https://almd-solutions.com

Company type

Public

Founded year

2001

Operating status

Operating

Headcount range

11–50 employees

Short description

AllMeD Solutions Ltd. (TASE: ALMD) is an Israeli medical device company developing minimally invasive cardiovascular and embolic protection products, with its core subsidiary True Leaf advancing a mitral valve regurgitation treatment through clinical trials.

Ownership category

akta.pro rank

Product category

Minimally Invasive Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Structural Heart Valves (TAVR/SAVR) & Valve Repair (HLAHAFAB)

Keywords

• Minimally invasive medical devices
• Cardiovascular intervention devices
• Mitral valve repair systems
• Embolic protection systems
• Urological stents

Headquarters

HQ city

Caesarea

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Medical Device Manufacturing and Sales: AllMeD Solutions Ltd develops, manufactures and markets minimally invasive medical products internationally. Products are used by physicians to treat a wide range of diseases and patients worldwide.

Distribution channels1 record

Marketing channels3 records

Core offering

AllMeD Solutions Ltd. (TASE: ALMD) develops, manufactures, and markets minimally invasive medical products internationally. Its current portfolio centers on the TruLeaf division's mitral valve docking system for valve-in-docking-station implantation (in clinical trials) and the ProCatid distal embolic protection system — an independent filter unit compatible with any commercially marketed guide wire. Previously owned divisions Allium Stents (urological stents) and Gardia Medical (embolic protection devices) have been divested.

Product overview

AllMeD Solutions Ltd. is a publicly traded company (TASE: ALMD) that develops, manufactures and markets minimally invasive medical products internationally. The company's portfolio includes its core subsidiary TruLeaf, which focuses on mitral valve regurgitation solutions with a docking system for valve replacement, and the ProCatid System, a distal embolic protection system. Previously sold subsidiaries include Allium Stents (urological stents) and Gardia Medical (embolic protection devices). The company invests in minimally invasive interventions that improve patient recovery processes.

Differentiator

Problem solved

Functional benefit

Brands

• True Leaf: Division developing solutions for mitral valve regurgitation treatment
• ProCatid Medical

Products and services

• TruLeaf Mitral Valve Docking System A minimally invasive mitral valve regurgitation solution consisting of a docking system that supports valve-in-docking-station implantation. Developed for patients with mitral valve regurgitation affecting millions of people worldwide. Phase I and Phase II human implantations have been performed by the True Leaf division.
• ProCatid Distal Embolic Protection System A distal embolic protection system (formerly known as WIRION by Gardia Medical) comprising an independent Filter Unit that can be delivered, locked, and deployed on any commercially marketed guide wire. Used by physicians during carotid and peripheral arterial catheter-based procedures.
• Needle-Stick Heart Valve Replacement Procedure First-in-human minimally invasive needle-stick procedure for replacing heart valves without open-heart surgery, performed on patients with severe heart failure caused by valve issues. Delivered rapid clinical improvements.

Quantifiable outcome

• Rapid clinical improvements observed in patients with severe heart failure caused by valve issues following needle-stick procedure

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core and minor.

• TruLeaf MedicalcoreStrategic or Co-development PartnerTruLeaf is a subsidiary of AllMeD Solutions developing the mitral valve regurgitation solution. The subsidiary has received Ethics Committee approval for human clinical trials in South Africa and R&D grant from Israel Innovation Authority. Phase I and Phase II human implantations have been performed.
• Dahlhausen Medical EquipmentminorOthersAcquired Allium Stents (fully covered diverse portfolio of urological stents) from AllMeD Solutions.
• Cardiovascular Systems, Inc (CSI)minorOthersAcquired Gardia Medical (embolic protection devices for carotid and peripheral arterial procedures) from AllMeD Solutions. CSI is now a subsidiary of Abbott, USA.

Scale indicators3 records

Recent moves8 records

Expansion highlights4 records

Broad incumbents

• Boston Scientific: Large incumbent with structural heart, peripheral intervention, and embolic protection (Watchman) franchises. Competes with AllMeD in embolic protection procedures and has been acquisitive in structural heart (e.g., bolt-on mitral investments).
• Medtronic: Diversified medical device incumbent with a structural heart portfolio (Evolut TAVR, Intrepid TMVR). Comparable to AllMeD in targeting structural heart disease, though Medtronic operates at vastly greater scale across many other device categories.
• Abbott: Acquired Gardia Medical (AllMeD's former subsidiary) via Cardiovascular Systems, Inc., and operates a major structural heart and vascular franchise including Tendyne (TMVR) and embolic protection. Directly comparable to AllMeD's former and current product categories.

Direct peers

• Cardiac Dimensions: Privately held developer of the Carillon Mitral Contour System, a transcatheter mitral annuloplasty device for functional mitral regurgitation. Direct peer to TruLeaf in targeting mitral regurgitation via minimally invasive, catheter-based approaches.
• Edwards Lifesciences: Global leader in structural heart therapies, including TAVR (sapien) and transcatheter mitral programs (PASCAL, Cardioband). Edwards is the most direct strategic competitor in mitral valve regurgitation treatment, the same condition TruLeaf is targeting.
• 4C Medical Technologies: Early-stage company developing the AltaValve transcatheter mitral valve system, designed for MR treatment without requiring native annular anchoring. Competes in the same mitral regurgitation treatment space as TruLeaf with a similar clinical-stage profile.
• JenaValve Technology: Clinical-stage developer of transcatheter aortic and mitral valve technologies, including transfemoral TAVR and AR treatment. Highly comparable in stage, focus area, and minimally invasive structural heart mission to AllMeD's TruLeaf division.
• InnovHeart: Developer of transcatheter mitral valve replacement (saturn) technology, targeting mitral regurgitation through a minimally invasive approach. Closely comparable in technology category, stage, and target indication to AllMeD's TruLeaf.
• Emboline: Developer of the Emboliner total embolic protection catheter for use during transcatheter aortic valve replacement and other structural heart procedures. Direct peer to AllMeD's ProCatid embolic protection system in the embolic protection device category.

Emerging players

• InspireMD: Commercial-stage company focused on embolic prevention and cerebral protection systems, including the CGuard carotid stent and the SwitchGuard neuroprotection system. Comparable to ProCatid in targeting embolic protection during catheter-based cardiovascular procedures.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AllMeD Solutions